- Meet Consumers/Patients
|Short bowel, short answer?|
J. Nightingale, Department of Gastroenterology, Leicester Royal Infirmary
Patients with short bowel syndrome or intestinal damage (e.g. from ischaemia, irradiation, necrotising enterocolitis etc,) will be interested to know that new information has been released on GLP-2, a growth hormone which may promote bowel adaptation. GLP-2 has been used to promote villus/crypt growth in the small and large bowel and to increase the length and weight of the small and large bowel in mice. New research by Jeppesen et al published in the October, 1999 issue of Gut shows that GLP-2 concentrations are low in patients with an end jejunostomy (lacking an ileum and colon). This may explain why these patients show less evidence of structural or functional intestinal adaptation over time. In his summary of Jeppesen’s research, J. Nightingale suggests that GLP-2 may be given to patients with short bowel syndrome or intestinal damage to promote adaptation in the future. At present, GLP-2 is in the research stage of development.